RNA-Binding Modulatory Compounds for Parasitic Embryogenesis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antihelminthic treatments are ineffective in preventing parasitic re-infection due to resistance development in parasites, particularly in developing countries, and fail to target parasitic worm embryos, leading to chronic health issues in humans and livestock.
Innovation Solution
Development of RNA-binding modulatory compounds that inhibit the activity of MEX-3, MEX-5, and POS-1 proteins essential for parasitic worm embryogenesis, providing a novel approach to treat and prevent parasitic infestations by targeting the embryonic stage of parasites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antihelminthic treatments are used to treat parasitic infestations, then the parasitic burden is reduced, but the parasites develop resistance and re-infection occurs
Solution Approach 1:
The patent changes the molecular target parameter from ion channels/receptors to RNA-binding proteins (MEX-3, MEX-5, POS-1) involved in embryogenesis. This parameter change creates a novel mechanism of action that does not rely on the same targets as existing antihelminthics, thereby avoiding resistance development and enabling effective treatment and prevention of re-infection
Solution Approach 2:
The patent targets embryonic stage parasites specifically, preventing them from developing into infective adults. By acting on embryos before they mature, the treatment prevents future re-infection cycles, addressing the root cause of persistent parasitic burden rather than just treating active infections
2Productivity
If current antihelminthic treatments are used, then active parasitic infestations are treated, but embryos that cause re-infection are not inactivated
Solution Approach 1:
The patent applies preliminary action by targeting embryonic parasites before they mature into infective adults. The RNA-binding modulatory compounds interfere with embryogenesis, preventing embryos from developing into worms that would cause re-infection. This early intervention ensures both treatment of active infestations and prevention of future re-infection cycles
Solution Approach 2:
The patent changes the target parameter from adult parasitic structures (ion channels, receptors) to embryonic developmental processes (RNA binding, embryogenesis). This parameter change enables the treatment to affect embryos specifically, achieving both immediate treatment efficacy and long-term prevention of re-infection
3Productivity
If repeated doses of antihelminthic drugs are administered, then parasitic infestations are treated, but resistance develops in the parasites
Solution Approach 1:
The patent changes the molecular target parameter from conventional ion channels and receptors to RNA-binding proteins (MEX-3, MEX-5, POS-1) that are essential for embryogenesis. This parameter change creates a fundamentally new mechanism of action that does not rely on the same targets as existing antihelminthics, thereby preventing resistance development even with repeated dosing
Solution Approach 2:
The patent targets a vulnerable embryonic stage that is transient and essential for parasite survival. By acting on this critical, short-lived embryonic phase, the treatment achieves high efficacy with fewer doses, reducing the opportunity for resistance development compared to chronic treatment of adult parasites
Data Source
AI summary
The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders.